{"id":1007108,"date":"2026-09-30T09:05:48","date_gmt":"2026-09-30T13:05:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/"},"modified":"2026-09-30T09:05:48","modified_gmt":"2026-09-30T13:05:48","slug":"lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/","title":{"rendered":"L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14"},"content":{"rendered":"

<\/p>\n

L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14<\/b><\/p>\n

Developed Through ai\u00b2 Accelerator\u2122, Qare\u2122 Is Designed to Enable Users to Compare Their Experiences Against Cohorts of People Like Them, with Additional Drug Classes Expected to Follow<\/i><\/b><\/p>\n

RUTHERFORD, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE<\/a>)–
\nL\u014dkahi Therapeutics\u2122, a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced Qare\u2122, a comparative health platform designed to evaluate treatment outcomes by comparing experiences across patients using different medications within the same therapeutic class. Introduced on National GLP-1 Day, Qare\u2122 is expected to become publicly available on October 14, 2026.<\/p>\n

\nLaunching initially in the GLP-1 category, Qare\u2122 is designed to provide a platform for GLP-1 users, regardless of product, to document, organize, and analyze their treatment experiences relative to others on a similar journey. L\u014dkahi is introducing Qare\u2122 to address a significant gap in healthcare data by helping patients answer a simple but important question: “How does my treatment experience compare to others like me?”<\/i><\/p>\n

\nWhile traditional health data tools focus primarily on individual tracking and recordkeeping, Qare\u2122 is designed as a comparative health platform that places treatment experiences within the context of real-world patient cohorts. L\u014dkahi believes this approach may advance comparative health intelligence by providing greater visibility into how patients experience therapies across a treatment category. Qare\u2122 is designed to empower patients to evaluate how their treatment experiences compare with those of similar patients using different medications, with the goal of creating greater accountability throughout the treatment process.<\/p>\n

\nL\u014dkahi selected National GLP-1 Day for the introduction of Qare\u2122 to spotlight the growing importance of patient-driven health data and encourage broader conversations around treatment transparency, medication experiences, and real-world comparative insights. Additional therapeutic categories are expected to be added in future releases.<\/p>\n

\n\u201cHealthcare data is a big business that fails to deliver meaningful value to patients. L\u014dkahi is changing that. Patients deserve a platform that allows them to ask, \u2018Am I on the right product for me, or am I taking it simply because my physician prescribed it?\u2019\u201d said Erik Emerson, Chief Executive Officer of L\u014dkahi Therapeutics\u2122. He added, \u201cToday, the global healthcare analytics market is approaching $70 billion, yet the people who generate that data, patients, do not benefit from it. Enough. We believe Qare\u2122 will help change that dynamic by putting patients at the center of the conversation. Today we introduce that vision, and beginning October 14, patients will be able to experience Qare\u2122 for themselves.\u201d<\/p>\n

\nMr. Emerson continued, \u201cQare\u2122 brings treatment to life every day. Treatment is an everyday experience, and when patients consider the money they spend, the emotional investment they make, and the hope they place in achieving success, it is remarkable how little visibility they have into how their experience compares with others facing similar circumstances. Qare\u2122 was built to help answer those questions.\u201d<\/p>\n

\nL\u014dkahi has a vision for Qare\u2122, and this is only the first step. L\u014dkahi believes that, through continued development of the technology supporting Qare\u2122, the platform can contribute to broader conversations about how healthcare data is collected, evaluated, and utilized. Medications need to be developed more quickly, results need to be aggregated more efficiently, and the overall process should become more accessible and cost-effective. L\u014dkahi cannot promise it will achieve these goals alone, but it can promise that the conversation begins today.<\/p>\n

Visit<\/b>qare-app.com<\/b><\/a>to learn more about Qare\u2122 and receive updates ahead of its October 14, 2026 public availability.<\/b><\/p>\n

About L\u014dkahi Therapeutics\u2122<\/b><\/p>\n

\nL\u014dkahi Therapeutics is a capital-efficient biopharmaceutical platform company focused on identifying, evaluating, acquiring, and advancing overlooked therapeutic assets. Through its ai\u00b2 platform and ai\u00b2 Futures Lab execution model, L\u014dkahi integrates cross-functional expertise and disciplined decision-making to drive strategic development and long-term value creation. For more information, please visit www.lokahithera.com<\/a>. For more information about the ai\u00b2 Division program, please visit www.ai2equals.com<\/a>. Information on the company\u2019s websites does not constitute a part of and is not incorporated by reference into this press release.<\/p>\n

About Glucotrack, Inc.<\/b><\/p>\n

\nGlucotrack, Inc. (NASDAQ: GCTK) operates L\u014dkahi and, through its subsidiary Glucotrack Technologies, Inc., is also focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use. For more information, please visit www.glucotrack.com<\/a>. Information on the company\u2019s website does not constitute a part of and is not incorporated by reference into this press release.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate,\u201d “believe,\u201d “expect,\u201d “plan,” \u201cintend,\u201d and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to: the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations, or otherwise); risks relating to the development, launch, and market acceptance of the Qare\u2122 platform; the ability to achieve user adoption and engagement with Qare\u2122; competition in the healthcare analytics and digital health markets; the ability to expand Qare\u2122 to additional therapeutic categories on the anticipated timeline; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260930351610\/en\/<\/a><\/span><\/p>\n

L\u014dkahi Therapeutics\u2122
\n<\/b>
ir@lokahithera.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California New Jersey<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Technology Diabetes Health General Health Pharmaceutical Health Technology Apps\/Applications Software Internet Fitness & Nutrition<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14 Developed Through ai\u00b2 Accelerator\u2122, Qare\u2122 Is Designed to Enable Users to Compare Their Experiences Against Cohorts of People Like Them, with Additional Drug Classes Expected to Follow RUTHERFORD, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE)– L\u014dkahi Therapeutics\u2122, a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced Qare\u2122, a comparative health platform designed to evaluate treatment outcomes by comparing experiences across patients using different medications within the same therapeutic class. Introduced on National GLP-1 Day, Qare\u2122 is expected to become publicly available on October 14, 2026. Launching initially in the GLP-1 category, Qare\u2122 is designed to provide a platform for GLP-1 users, regardless … <\/p>\n

Continue reading “L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1007108","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nL\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14 Developed Through ai\u00b2 Accelerator\u2122, Qare\u2122 Is Designed to Enable Users to Compare Their Experiences Against Cohorts of People Like Them, with Additional Drug Classes Expected to Follow RUTHERFORD, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE)– L\u014dkahi Therapeutics\u2122, a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced Qare\u2122, a comparative health platform designed to evaluate treatment outcomes by comparing experiences across patients using different medications within the same therapeutic class. Introduced on National GLP-1 Day, Qare\u2122 is expected to become publicly available on October 14, 2026. Launching initially in the GLP-1 category, Qare\u2122 is designed to provide a platform for GLP-1 users, regardless … Continue reading "L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-30T13:05:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260930351610r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14\",\"datePublished\":\"2026-09-30T13:05:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\\\/\"},\"wordCount\":1168,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260930351610r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\\\/\",\"name\":\"L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260930351610r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-09-30T13:05:48+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260930351610r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260930351610r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/","og_locale":"en_US","og_type":"article","og_title":"L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14 - Market Newsdesk","og_description":"L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14 Developed Through ai\u00b2 Accelerator\u2122, Qare\u2122 Is Designed to Enable Users to Compare Their Experiences Against Cohorts of People Like Them, with Additional Drug Classes Expected to Follow RUTHERFORD, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE)– L\u014dkahi Therapeutics\u2122, a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced Qare\u2122, a comparative health platform designed to evaluate treatment outcomes by comparing experiences across patients using different medications within the same therapeutic class. Introduced on National GLP-1 Day, Qare\u2122 is expected to become publicly available on October 14, 2026. Launching initially in the GLP-1 category, Qare\u2122 is designed to provide a platform for GLP-1 users, regardless … Continue reading \"L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-30T13:05:48+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260930351610r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14","datePublished":"2026-09-30T13:05:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/"},"wordCount":1168,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260930351610r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/","name":"L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260930351610r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-09-30T13:05:48+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260930351610r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260930351610r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lokahi-therapeutics-announces-qare-the-first-real-time-comparative-health-platform-for-glp-1-medications-with-public-availability-beginning-october-14\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"L\u014dkahi Therapeutics\u2122 Announces Qare\u2122, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1007108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1007108"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1007108\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1007108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1007108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1007108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}